$-3.43
(Market cap
$30,618 Mln
Revenue (TTM)
$16,632 Mln
P/E Ratio
22.8
P/B Ratio
5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$1,111 Mln
-
ROE
0.2 %
-
ROCE
6.3 %
-
Industry P/E
--
-
EV/EBITDA
12.8
-
Debt to Equity
2.2
-
Book Value
$37.3
-
EPS
$8.1
-
Face value
--
-
Shares outstanding
166,900,000
10 Years Aggregate
CFO
$14,718.45 Mln
EBITDA
$19,632.32 Mln
Net Profit
$6,311.59 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
IQVIA Holdings (IQV)
| -18.6 | 14.0 | 3.1 | 24.0 | -3.1 | -4.7 | 10.6 |
|
BSE Sensex
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P 100
| 5.5 | 2.6 | 8.6 | 24.9 | 22.1 | 13.7 | 14.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
IQVIA Holdings (IQV)
| 14.7 | -15.0 | 12.9 | -27.4 | 57.5 | 16.0 | 33.0 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
IQVIA Holdings (IQV)
|
183.5 | 30,617.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.8 | 5.0 |
| 303.1 | 40,461.0 | 4,286.9 | 577.2 | 9.8 | 88.2 | 76.3 | 37.6 | |
| 94.2 | 20,422.4 | 819.6 | -1,183.8 | -141.4 | -143.4 | -- | 29.0 | |
| 74.5 | 12,308.8 | 1,057.9 | -326.6 | -16.4 | -58.9 | -- | 25.0 | |
| 47.4 | 18,823.5 | 2,225.0 | -3,194.0 | -143.4 | -38.2 | -- | 2.5 | |
| 163.9 | 16,478.1 | 3,102.4 | 668.6 | 27.4 | 20.9 | 25.2 | 4.8 | |
| 635.5 | 66,620.0 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 15.5 | 2.1 | |
| 14.8 | 11,463.9 | 0.0 | -872.2 | -- | -287.7 | -- | 21.0 | |
| 549.9 | 23,340.2 | 3,169.8 | 1,287.4 | 51.4 | 20.6 | 20.3 | 4.0 | |
| 446.8 | 113,407.9 | 12,255.1 | 4,338.3 | 31.7 | 23.7 | 26.5 | 5.9 |
Shareholding Pattern
View DetailsAbout IQVIA Holdings (IQV)
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments:... Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina. Read more
-
CEO & Chairman
Mr. Ari Bousbib
-
CEO & Chairman
Mr. Ari Bousbib
-
Headquarters
Durham, NC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for IQVIA Holdings (IQV)
What is the current share price of IQVIA Holdings Inc (IQV) Today?
The share price of IQVIA Holdings Inc (IQV) is $183.45 (NYSE) as of 05-Jun-2026 16:00 EDT. IQVIA Holdings Inc (IQV) has given a return of -3.06% in the last 3 years.
What is the current PB & PE ratio of IQVIA Holdings Inc (IQV)?
The P/E ratio of IQVIA Holdings Inc (IQV) is 22.79 times as on 05-Jun-2026.
The P/B ratio of IQVIA Holdings Inc (IQV) is 5.01 times as on 05-Jun-2026, a 13 premium to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
28.49
|
5.96
|
|
2024
|
25.88
|
5.86
|
|
2023
|
31.40
|
6.98
|
|
2022
|
35.42
|
6.70
|
|
2021
|
56.90
|
9.10
|
What is the 52 Week High and Low of IQVIA Holdings Inc (IQV)?
The 52-week high and low of IQVIA Holdings Inc (IQV) are Rs 247.05 and Rs 146.44 as of 07-Jun-2026.
What is the market cap of IQVIA Holdings Inc (IQV)?
IQVIA Holdings Inc (IQV) has a market capitalisation of $ 30,618 Mln as on 05-Jun-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in IQVIA Holdings Inc (IQV)?
Before investing in IQVIA Holdings Inc (IQV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.